Learning experience: studied at Beijing University of Science and Technology from September 2001 to January 2008, bachelor and master degree, majored in iron and steel metallurgy, and has studied at School of Metallurgy and ecological engineering, Beijing University of Science and Technology since September 2013, serving as a doctoral candidate. Work experience: Prior to December 2008, I was stationed at Shougang Qiangang Company, and later at Shougang Jingtang Company. From May 2008 to February 2014, I worked at the Thin Plate Institute of Shougang Technology Research Institute. Since March 2014, I have been the Deputy General Manager of AVIC Shangda High Temperature Alloy Materials Co., Ltd. Next step in introducing foreign experts: AVIC Shangda High Temperature Alloy Materials Co., Ltd. plans to hire David Fitchett, a retired employee of Rolls Royce in the UK, in 2021. David Fitchett joined Rolls Royce in the UK in 1976 and has been working in the company's international business cooperation department for the procurement and supply chain management of global suppliers of high temperature alloy materials and components until the end of 2019, serving as a senior project manager for the department for a long time. From 2000 to 2019, he was responsible for the procurement and management of raw materials and components for civil aviation engines in China. Considering the expansion of AVIC Shanghai's products into overseas markets and its grasp of global market trends and product research and development, AVIC Shanghai plans to hire him as a senior consultant for the company's global high-temperature alloy material and return business development, responsible for the specific implementation of the above work and regularly reporting to AVIC Shanghai.

October, 1978 to October, 1980, studied in Xingtai Finance and Trade School October, 1980 to December, 1992, Deputy Manager and General Accountant of Weixian Local Products Company December, 1992 to December, 1995, General Manager of Weixian United Purchase and Marketing Company December, 1995 to May, 2002, General Manager of Weixian Agricultural means of production General Company May, 2002 to August, 2005, General Manager of Xingtai Weiyuan Agricultural Means of Production Group Co., Ltd. August, 2005 to December, 2010, Chairman of Hebei Yuanda International Fertilizer Co., Ltd From December 2010 to present, the Chairman and General Manager of Genlido Biotechnology Co., Ltd. plan to introduce experts and technologies from the San Joaquin Valley Agricultural Science Center of the US Department of Agriculture Research Institute and the Plant Health Laboratory of the Alberta Department of Agriculture and Forestry in Canada. The main technical requirements for introducing the US Department of Agriculture laboratory are related technologies for microbial improvement of saline soil, and improving the product development and technical level of Genlido Co., Ltd. in microbial soil amendments. The main technical requirements for introducing the Alberta Plant Health Laboratory in Canada are related technologies for using microbial fertilizers to improve plant resistance to drought, salinity, diseases and pests, Enhance the product development and technical level of Genliduo Co., Ltd. in the field of microbial plant inducers.

Study experience: 19809-19835 Bachelor's degree in Clinical Medicine, Department of Medicine, Taipei Medical College 19929-19945 Master's degree in Pediatric Medicine, Institute of Clinical Medicine, Kaohsiung Medical College 19949-19973 Master's degree in Public Health, School of Public Health, Hopkins University, USA 19979-20015 Doctoral degree in Public Health, Hopkins University, USA Work experience: 199612 Distinguished Professor, Hawaii State University, USA 199704 Distinguished Professor, Johns Hopkinson University, USA 199907 National Institutes of Health, 2001 Zhongshan Executive Director of the University Biological Education Center 200212 Deputy Director of the Institute of Traditional Chinese Medicine at Capital Medical University 200310 Doctoral Supervisor of the School of Life Sciences at Jinan University 200606 Counselor of the United Nations Educational, Scientific and Cultural Organization 200609 Senior Advisor of the World Health Organization Southern Europe Cooperation Center 2009 Executive Director of Neox Biopharmaceutical Technology Co., Ltd. 201312 Nobel Prize winner Dr. Murad Vice Dean of the Institute of Translational Sciences 201510 Founder of the Jingding Great Health Industrial Park 2016 Dr. Smoot, Chairman of Taiwan Asia Biochemical Technology Co., Ltd., won the Nobel Prize in January 2017, and Dean of the Academy of Translational Sciences. On January 2018, a representative of Japan Kyoyang Corporation banned the Targeted Brain Hypothermia Project. Dr. Lin Hengyi, a representative of Asia Pacific Medical Technology Development Co., Ltd., signed a cooperation agreement for the "China Giant Deer Medical Device Manufacturing and Distribution Base" project. The total planned investment for the project is 250 million yuan. To build a medical device manufacturing and distribution base in our park, this project mainly involves the construction of the first Aike membrane machine (i.e. an extracorporeal membrane lung care machine) with independent intellectual property rights produced in China, and the construction and production of the world's first three-in-one Aike membrane medical device that stabilizes blood pressure and cools the temperature. 2、 The 6D targeted tumor treatment bed has been developed in collaboration with Taiwan's Zion Biotechnology Co., Ltd. The 6D targeted tumor treatment bed obtained the medical device license number issued by the US Food and Drug Administration in June 2019. The 6D targeted tumor treatment bed, designed with a six degree of freedom axis and equipped with an intelligent robotic arm, enables the treatment bed that carries patients to treat them in an automated process, improving the accuracy of cancer treatment, and reducing the medical harm caused by the human body during radiation therapy. The total investment of this project is planned to be 100 million yuan, covering an area of 2500 square meters and a total construction area of 4000 square meters. After the production of the 6D targeted tumor treatment bed project, the first domestically produced 6D targeted tumor treatment bed will be manufactured and produced in our park, breaking through the long-standing technical barriers faced by Europe, America, and Japan in China. The 6D targeted tumor treatment bed in this project can accelerate the speed and accuracy of cancer treatment and examination, thereby reducing the proportion of deaths among Chinese people due to cancer and tumor diseases, and achieving significant social benefits.

1、 Hebei Ji Microbial Technology Co., Ltd. was established in 2002 and is headquartered in Baoding Prefecture, Fudi Prefecture, Beijing. Adhering to the business philosophy of "operation according to law, equality and voluntariness, safety and stability, and market operation", the company takes restoring ecological agriculture and creating green agriculture as its own responsibility, applies the national 863 project, and is committed to the research, development, production and promotion of microbial functional bacteria raw materials, agricultural microbial agents, and bio organic fertilizers with unique industry concepts and bacteria and fertilizer production processes. After extensive testing and application, our company's products have significant effects on disease prevention, yield increase, organic and taste improvement of crops, and can continuously improve and repair soil, promoting ecological restoration of farmland. Hebei Ji Microbial Technology Co., Ltd. is a high-tech company that integrates scientific research, development, production, and operation. It aims to create an annual production capacity of 20000 tons of high content liquid microbial inoculants and 10000 tons of high content soluble microbial bacterial powder and 100000 tons of bio organic fertilizer. The company relies on the technological advantages of Hebei Agricultural University, Hebei University, and Hebei Provincial Institute of Microbiology, and through modern enterprise operation models such as production research integration and joint entrepreneurship with technology experts, has attracted well-known microbiological and agricultural technology experts in the field of bioengineering research and application in China, We have established the "Jiwei R&D Center" and "Expert Service Team" to provide technical support for industry partners and users. Currently, we have developed and produced "Jiwei Active Phosphorus Potassium Microbial Seed Agent", "Baowei Guoyou 100 Microbial Seed Agent" The series of products such as Jiwei Duokang 58 Micro "Biological Bacterial Seed Agent and Its Microbial Phosphorus Potassium Fertilizer" have been promoted in more than 20 provinces, cities, and districts across the country, with a cumulative application area of nearly 200 million acres. Some of the products are also exported to countries such as Thailand, North Korea, Malaysia, and have been designated as experimental and export products by the "International Microbial Fertilizer Training Class" and "Semiarid Area Agricultural Production International Training Class", and have been awarded the "Top 10 Green, Pollution-free, and Environmentally Friendly Fertilizers in China" Multiple honors such as "Hebei Province Product Quality Inspection Qualified Enterprise". Hebei Ji Microbial Technology Co., Ltd. is based on the Agricultural Microbial Engineering Technology Research Center of Hebei Agricultural University, with advanced instruments and equipment, sufficient personnel, and a team with excellent quality, excellent business, mature technology, and combat effectiveness. The company pioneered the post-treatment processes of "centrifugal concentration+flash drying" and "centrifugal concentration+spray drying" of fermentation broth. The former can concentrate the bacteria content 20 times, while the latter can concentrate the bacteria content 100 times. This process has been used in the production of highly concentrated Bacillus thuringiensis powder since 2008, resulting in a higher number of live bacteria, lower water content, and longer shelf life for Bacillus thuringiensis products. It is the first in China and is currently the most advanced microbial agent post-treatment process in the world. As a result, the company has won the Hebei Province Science and Technology Progress Award for its production technology and process. The plan is to introduce experts with more academic prestige in improving soil microecology.

1. It is planned to introduce high-end technical talents in the industry, increase the investment in research and development, take innovative drug research, upgrading and transformation of traditional biochemical drug preparations, evaluation of consistency of quality and efficacy of generic drugs as the research and development direction, and take the development of high value-added products with independent intellectual property rights as the development goal to build a more integrated, systematic, mature and progressiveness drug comprehensive research and development platform. We will enhance the company's independent innovation capabilities and promote technological development cooperation with universities and research institutes. 2. We plan to introduce advanced high-end equipment and technologies from abroad, such as the introduction of world-class biotechnology (such as protein purification, bidirectional hydrolysis, chromatography separation, etc.), cooperation with Dr. Zhang Min's new research team from GLB Corporation in Japan, and advanced technologies such as industrialized fermentation and extraction technology, emulsification phenomenon treatment, and separation of various alkaloid components, to break through the bottleneck of industrialization.

1. It is planned to introduce high-end technical talents in the industry, increase the investment in research and development, take innovative drug research, upgrading and transformation of traditional biochemical drug preparations, evaluation of consistency of quality and efficacy of generic drugs as the research and development direction, and take the development of high value-added products with independent intellectual property rights as the development goal to build a more integrated, systematic, mature and progressiveness drug comprehensive research and development platform. We will enhance the company's independent innovation capabilities and promote technological development cooperation with universities and research institutes. 2. We plan to introduce advanced high-end equipment and technologies from abroad, such as the introduction of world-class biotechnology (such as protein purification, bidirectional hydrolysis, chromatography separation, etc.), cooperation with Dr. Zhang Min's new research team from GLB Corporation in Japan, and advanced technologies such as industrialized fermentation and extraction technology, emulsification phenomenon treatment, and separation of various alkaloid components, to break through the bottleneck of industrialization.

Introduce 1-3 foreign experts (majoring in biochemistry, biopharmaceuticals, and molecular biology), introduce high-level, refined, and cutting-edge talents from abroad to carry out scientific research work in the center, actively carry out research on the application of cutting-edge and upstream technologies, accelerate the transformation of independent innovation achievements, and promote the international development of the biopharmaceutical industry in our province.

Company profile: Hebei Dijieo Technology Co., Ltd. (hereinafter referred to as Dijieo), English name: HebeiDSF-GEOSTechnology Co, Ltd. was established on February 18, 2019, with a registered capital of 3 million RMB. It officially settled in the Beijing Tianjin Hebei Entrepreneurship Incubation Base in September 2019. It is a Sino foreign joint venture enterprise focused on technological innovation, research and development, and high-tech services. Having the ability to independently research and manufacture corresponding high-end instruments, equipment, and software development, it meets the many incentive conditions in the fields of geophysical exploration and biomedicine in the latest "Catalogue of Encouraged Foreign Investment Industries" issued and implemented by the country. The predecessor of Diageo is "MAC · SAI", a Ukrainian special aviation industry multi field airline. The founding members are members of the original core team of "MAC · SAI". Through continuous exploration, exploration, combination and practice of passive source geophysical technology, aviation technology and bio electromagnetic technology, it has laid a solid scientific foundation for the creation, technological innovation and development of Diageo. On November 8, 2019, the company obtained the provincial technology oriented small and medium-sized enterprise certificate issued by the Hebei Provincial Department of Science and Technology, with certificate number KZX201911130011. Since its establishment in 2019, it has been included in the national technology oriented small and medium-sized enterprise directory for two consecutive years. The 2019 year number is 2019130730B0003276, and the 2020 year number is 20201307300000445. Base salary: 8000 Performance: 2000 Insurance: According to the implementation measures and requirements of social security and medical insurance for foreigners working in China, welfare benefits are implemented. According to the company's salary and welfare standards, experts are paid in full on a monthly basis, and a performance reward incentive mechanism is implemented for experts according to performance management measures. In terms of daily life, the company is responsible for providing free accommodation and reception for experts, ensuring their normal, orderly and safe living needs during their work at the company. All expenses for obtaining work permits for experts coming to China (except for their domestic visas) shall be borne by the company. Related policies: According to the national implementation and management measures for the introduction and work of foreign experts in China

1990.5-1995.6 Student in Clinical Medicine, Zhangjiakou Medical College 1995.7-2001.8 Resident Physician in Head and Neck Surgery, Tangshan People's Hospital 2001.9-2004.7 Master's Candidate in Oncology, Tianjin Medical University 2004.8-2012.4 Deputy Chief Physician in Head and Neck Surgery, Tangshan People's Hospital 2006.5-2012.4 Deputy Chief Physician and Head and Neck Surgery, Tangshan People's Hospital 2012.4- Present Chief of Science and Education Department, Otolaryngology Head and Neck Surgery, Tangshan People's Hospital From September 2014 to March 2015, the director was sponsored by young and middle-aged scholars from the Hebei Association for Science and Technology to conduct scientific and technological exchanges abroad. As a visiting scholar, he went to the famous MD Anderson Cancer Center in the United States, the Memorial Sloan Kettering Cancer Center in New York, the Massachusetts General Hospital of Harvard University School of Medicine, the Eye and Ear Hospital, John Hopkins Hospital, Barnes Jewish Hospital affiliated with the University of Washington (St. Louis) School of Medicine As a clinical visiting scholar at Baptist Hospital of Wake Forest University School of Medicine, I focus on learning the latest international diagnostic and treatment methods for head and neck tumors, especially thyroid and parotid gland tumors. 1. Continue to invite Professor Cui Quanjun, an orthopedic expert from the University of Virginia in the United States, to the hospital to carry out the "Sino US Orthopedic International Exchange Activity", which will drive the rapid improvement of our orthopedic professional diagnosis and surgical practice capabilities. Next, with the development of surgical technology, we will discuss scientific research cooperation with Professor Cui's team, striving to apply for support for 1-2 Hebei Provincial Science and Technology Plan projects and apply for the Hebei Provincial Science and Technology Progress Award. 2. We plan to invite experts from the University of Padua in Italy to introduce the technical project of "In vivo research on the electrical characteristics of soft tissue tumors". Main content: Standard preoperative tumor assessment, including the treatment of surgical samples such as radiation imaging and tumor biopsy. The treatment of electrode needle wounds in tumor tissue requires pathological testing before tumor treatment. Objective: Through exchange and learning, explore new medical technologies, promote cooperation in this field, fill domestic gaps, jointly build advantageous disciplines, and better serve society.

Assisting in applying for a visa to China is assisting in applying for a work permit to China. Welfare benefits include assisting in applying for a visa to China, obtaining a residence permit to China, and providing international round-trip airfare during your first visit to China. Accommodation issues during your stay in China can be resolved, and family members can be arranged to arrange for your children to come to China and provide medical examinations during their stay in China.